Tissue factor pathway inhibitor in childhood nephrotic syndrome

Pediatric Nephrology

Volumn 21, Issue 6, 2006, Pages 771-777

  Al Mugeiren, Mohamed M ^a   Abdel Gader, Abdel Galil M ^a   Al Rasheed, Saud A ^a   Al Salloum, Abdullah A ^a  

^a KING KHALID UNIVERSITY HOSPITAL   (Saudi Arabia)

Author keywords

Haemostasis; Nephrotic syndrome; TFPI; Tissue factor pathway inhibitor

Indexed keywords

ALBUMIN; CREATININE; FIBRINOGEN; PLASMINOGEN ACTIVATOR INHIBITOR; PREDNISOLONE; PROTEIN C; PROTEIN S; PROTHROMBIN; THROMBIN ANTITHROMBIN COMPLEX; TISSUE FACTOR PATHWAY INHIBITOR; TISSUE PLASMINOGEN ACTIVATOR; UREA;

ADOLESCENT; ALBUMIN BLOOD LEVEL; ARTICLE; CHILD; CHILDHOOD DISEASE; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; FIBRINOGEN BLOOD LEVEL; HUMAN; HYPERCOAGULABILITY; MAJOR CLINICAL STUDY; MALE; NEPHROTIC SYNDROME; PRIORITY JOURNAL; RELAPSE; REMISSION; RISK FACTOR; STATISTICAL SIGNIFICANCE; THROMBOSIS;

ADOLESCENT; CHILD; CHILD, PRESCHOOL; FEMALE; FIBRINOGEN; FIBRINOLYSIS; HUMANS; KIDNEY; LIPOPROTEINS; MALE; MONITORING, PHYSIOLOGIC; NEPHROTIC SYNDROME; PROTEIN C; PROTEIN S; STEROIDS; THROMBIN TIME;

EID: 33646696562     PISSN: 0931041X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00467-006-0061-2     Document Type: Article

References (48)

1. Livio M (1989) Hypercoagulability in the nephrotic syndrome. In: Remuzzi G, Rossi EC (eds) Haemostasis and the kidney. Butterworth, London, pp 145-152
2. Mehls O, Andrassy K, Koderisch J, Herzog U, Ritz E (1987) Hemostasis and thromboembolism in children with nephrotic syndrome: Differences from adults. J Pediatr 110:862-8677
3. Andrassy K, Ritz F, Bommer J (1980) Hypercoagulability in the nephrotic syndrome. Klin Wochenschr 58:1029-1036
4. Robert A, Olmer M, Sampol J, Gugliotta JE, Casanova P (1987) Clinical correlation between hypercoagulability and thrombo-embolic phenomena. Kidney Int 31:830-835
5. Anand NK, Chand G, Talib VH, Chellani H, Pande J (1996) Haemostatic profile in nephrotic syndrome. Indian Pediatr 33:1005-1012
6. Schlegel N (1997) Thromboembolic risks and complications in nephrotic children. Semin Thromb Hemost 23:271-280
7. Citak A, Emre S, Sirin A, Bilge I, Nayr A (2000) Haemostatic problems and thromboembolic complications in nephrotic children. Pediatr Nephrol 14:138-142
8. Elidrissy ATH, Gader AMA (1985) Antithrombin III (ATIII) and fibrinogen levels in nephrotic syndrome in children. Haemostasis 15:384-388
9. Elidrissy ATH, Abdurrahman MB, Bahakim HM, Jones MD, Gader AMA (1991) Haemostatic measurements in childhood nephrotic syndrome. Eur J Pediatr 150:374-378
10. Al Mugeiren MM, Gader AMA, Al-Rasheed SA, Bahakim HM, Al-Momen AK, Al-Salloum A (1995) Platelet aggregometry-dose related responses to arachidonic acid in childhood nephrotic syndrome. Platelets 6:71-74
11. Oviasu E, Famodu AA, Ojeh EA (1998) Plasma viscosity in nephrotic Nigerians. Clin Hemorheol Microcirc 19:163-167
12. Sahu S, Nageswari K, Banerjee R, Puniyani RR (1998) Hemorheological changes in nephrotic syndrome. Clin Hemorheol Microcirc 19:17-20
13. Bohler T, Linderkamp O, Leo A, Wingen AM, Scharer K (1992) Increased aggregation with normal surface charge and deformability of red blood cells in children with nephrotic syndrome. Clin Nephrol 38:119-124
14. Tsukahara H, Haruki S, Hiraoka M, Hori C, Sudo M (1997) Persistent hypercholesterolaemia in frequently relapsing steroid-responsive nephrotic syndrome. J Paediatr Child Health 33:253-355
15. Al-Mugeiren MM, Gader AMA, Al-Rasheed SA, Bahakim HM, Al-Momen AK, Al-Salloum A (1996) The coagulopathy of nephrotic syndrome-a reappraisal of the role natural anticoagulants and fibrinolysis. Haemostasis 26:304-310
16. Yermiahu T, Shalev H, Landau D, Dvilansky A (1996) Protein C and protein S in pediatric nephrotic patients. Sangre (Barc) 41:155-157
17. Vigano-D'Angelo S, D'Angelo A, Kauffmann CE, Sholer C, Esmon CT, Comp PC (1987) Protein S deficiency occurs in the nephrotic syndrome. Ann Intern Med 107:42-47
18. Gouault-Heilmann M, Gadelha-Parente T, Levent M, Intrator L, Rostoker G, Lagrue G (1988) Total and free protein S in nephrotic syndrome. Thromb Res 49:37-42
19. Bajaj MS, Birktoft JJ, Steer SA, Bajaj SP (2001) Structure and biology of tissue factor pathway inhibitor. Thromb Haemost 86:959-972
20. Rapaport SI (1991) The extrinsic pathway inhibitor. A regulator of tissue factor dependent blood coagulation. Thromb Haemost 66:6-15
21. Broze GJJ (1995) Tissue factor pathway inhibitor. Thromb Haemost 74:90-93
22. Sandset PM, Warn-Cramer BJ, Rao LVM, Maki SL, Rapaport SI (1991) Depletion of extrinsic pathway inhibitor (EPI) sensitizes rabbits to disseminated intravascular coagulation induced with tissue factor: evidence supporting a physiologic role for EPI as a natural anticoagulant. Proc Natl Acad Sci USA 88:708-712
23. Sandset PM, Warn-Cramer BJ, Maki SL, Rapaport SI (1991) Immunodepletion of extrinsic pathway inhibitor sensitizes rabbits to endotoxin-induced intravascular coagulation and the generalized Shwartzman reaction. Blood 78:1496-1502
24. Day KC, Hoffman LC, Palmier MO, Kretzmer KK, Huang MD, Pyla EY, Spokas E, Broze JGJ, Warren TG, Wun TC (1990) Recombinant lipoprotein-associated coagulation inhibitor inhibits tissue thromboplastin-induced intravascular coagulation in the rabbit. Blood 76:1538-1545
25. Bregengard C, Nordfang O, Wildgoose P, Svendsen O, Hedner U, Diness V (1993) The effect of two-domain tissue factor pathway inhibitor on endotoxin-induced disseminated intravascular coagulation in rabbits. Blood Coagul Fibrinolysis 4:699-676
26. Holst J, Lindblad B, Bergqvist D, Nordfang O, Ostergaard PB, Peterson JG, Nielsen G, Hedner U (1994) Antithrombotic effect of recombinant truncated tissue factor pathway inhibitor (TFPI-161) in experimental venous thrombosis-a comparison with low molecular weight heparin. Thromb Haemost 71:214-219
27. Ellis BC, Stransky A (1961) A quick and accurate method for the determination of fibrinogen in plasma. J Lab Clin Med 58:477-488
28. Areins RAS, Moia M, Rivolta E, Ponticelli C, Mannucci PM (1999) High levels of tissue factor pathway inhibitor in patients with nephrotic proteinuria. Thromb Haemost 82:1020-1023
29. Malyszko JS, Malyszko J, Mysliwiec M (1999) Tissue factor and inhibitor of the blood coagulation pathway in nephrotic syndrome. Pol Arch Med Wewn 101:301-305
30. Warshawsky I, Bu G, Mast A, Saffitz JE, Broze GJ Jr, Schwartz AL (1995) The carboxy terminus of tissue factor pathway inhibitor is required for interacting with hepatoma cells in vitro and in vivo. J Clin Invest 95:1773-1781
31. Palmier MO, Hall IJ, Reisch CM, Baidwin MK, Wilson AG, Wun TC (1992) Clearance of recombinant tissue factor pathway inhibitor (TFPI) in rabbits. Thromb Haemost 68:33-36
32. Narita M, Bu G, Olins GM, Higuchi DA, Herz J, Broze GJ Jr, Schwartz AL (1995) Two receptor systems are involved in the plasma clearance of tissue factor pathway inhibitor in vivo. J Biol Chem 270:24800-24804
33. Warshawsky I, Herz J, Broze GJ, Schwartz AL (1996) The low density lipo-protein receptor-related protein can function independently from heparin sulphate proteogylcans in tissue factor pathway inhibitor endocytosis. J Biol Chem 271:25873-25879
34. Eling M, Stephens AC, Oragui EE, Rivers RPA, Levin M (2001) Tissue factor pathway inhibitor (TFPI) levels in the plasma and urine of children with meningococcal disease. Thromb Haemost 85:240-244
35. Leurs PB, van Oerle R, Wolffenbuttel HR, Hamulyak K (1997) Increased tissue factor pathway inhibitor (TFPI) and coagulation in patients with insulin-dependent diabetes mellitus. Thromb Haemost 77:472-476
36. Alban S, Gastpar R (2001) Plasma levels of total and free tissue factor pathway inhibitor (TFPI) as individual pharmacological parameters of various heparins. Thromb Haemost 85:824-829
37. Hansen JB, Svensson B, Olsen R, Ezban M, Osterud B (2000) Heparin induces synthesis and secretion of tissue factor pathway inhibitor from endothelial cells in vitro. Thromb Haemost 83:937-943
38. Kemme MJ, Burggraaf J, Schoemaker RC, Cohen AF, Kluft C, Chia S, Webb DJ, Newby DE (2003) Local tissue factor pathway inhibitor release in the human forearm. Thromb Haemost 89:438-45
39. Novotny WF, Brown SG, Miletich JP, Rader DJ, Broze GJ Jr (1991) Plasma antigen levels of the lipoprotein-associated coagulation inhibitor in patient samples. Blood 78:387-393
40. Morishita E, Asakura H, Saito M, Yamazaki M, Ontachi Y, Mizutani T, Kato M, Matsuda T, Nakao S (2001) Elevated plasma levels of free-form of TFPI antigen in hypercholesterolemia patients. Atherosclerosis 154:203-212
41. Chesney RW (1999) The idiopathic nephrotic syndrome. Curr Opin Pediatr 11:158-161
42. Merouani A, Levy E, Mongeau JG, Robitaille P, Lambert M, Delvin EE (2003) Hyperlipidemic profiles during remission in childhood idiopathic nephrotic syndrome. Clin Biochem 36:571-574
43. Tkaczyk M, Owczarek D, Puczko-Nogal B, Makosiej R, Rogowska-Kalisz A, Ptasnik W, Finke D (2000) Activation of coagulation cascade in children during an idiopathic nephrotic syndrome relapse. Pol Merkuriusz Lek 8:226-227
44. Tkaczyk M, Baj Z (2002) Surface markers of platelet function in idiopathic nephrotic syndrome in children. Pediatr Nephrol 17:673-677
45. Schnaper HW (2001) Antithrombin III, protein S and coagulation in the nephrotic syndrome. Pediatr Nephrol 16:98
46. Loirat C, Hurtaud-Roux MF, Schlegel N, Brun P (1992) Thromboembolic complications in nephrotic syndrome. Pediatr Nephrol 6:C67
47. Svenson PJ, Dahlback B (1994) Resistance to activated protein C as a basis for venous thrombosis. N Engl J Med 330:517-522
48. Camisi S, Cavatoris F (1998) A case of deep vein thrombosis in idiopathic nephrotic syndrome with resistance to activated protein C. J Nephrol 11:76-77